Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1-Reference-Cited by-同舟云学术

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1

Published:2017-08-03 Issue:8 Volume:18 Page:1688
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Sochaj-Gregorczyk Alicja,Ludzia Patryk,Kozdrowska Emilia,Jakimowicz Piotr,Sokolowska-Wedzina Aleksandra,Otlewski Jacek

Funder

National Science Centre, Poland

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/18/8/1688/pdf

Reference67 articles.

1. Antibody–drug conjugates

2. Antibody-drug conjugates—an emerging class of cancer treatment

3. Antibody–drug conjugates as novel anti-cancer chemotherapeutics

4. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

5. Antibody–drug conjugates: current status and future directions

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy;Expert Opinion on Drug Discovery;2021-01-11

2. Tackling solid tumour therapy with small-format drug conjugates;Antibody Therapeutics;2020-11-25

3. Cytotoxicity evaluation of curcumin-loaded affibody-decorated liposomes against breast cancerous cell lines;Journal of Liposome Research;2020-07-03

4. Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1);Molecular Pharmaceutics;2020-06-05

5. Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint;Protein Expression and Purification;2020-02